Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety and side effects of cyclophosphamide given together with
dexamethasone in treating patients with castration resistant prostate cancer that has spread
to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving low doses of cyclophosphamide
daily may reduce side effects. Dexamethasone is a corticosteroid drug that is used to treat
some of the problems caused by chemotherapy treatment. The combination of cyclophosphamide
and dexamethasone may work better in treating patients with castration resistant prostate
cancer.